90 related articles for article (PubMed ID: 23235972)
1. Efficacy of taxotere, thalidomide, and prednisolone in patients with hormone-resistant metastatic prostate cancer.
Rezvani H; Haghighi S; Ghadyani M; Attarian H
Urol J; 2012; 9(4):673-7. PubMed ID: 23235972
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer.
Vordos D; Paule B; Vacherot F; Allory Y; Salomon L; Hoznek A; Yiou R; Chopin D; Abbou CC; de la Taille A
BJU Int; 2004 Sep; 94(4):524-7. PubMed ID: 15329105
[TBL] [Abstract][Full Text] [Related]
3. [AUO study AP 59/10: first-line therapy of castration-resistant prostate cancer].
Rexer H
Urologe A; 2011 Jun; 50(6):722-4. PubMed ID: 21584827
[No Abstract] [Full Text] [Related]
4. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
[TBL] [Abstract][Full Text] [Related]
5. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
[TBL] [Abstract][Full Text] [Related]
6. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
Hussain M; Tangen CM; Lara PN; Vaishampayan UN; Petrylak DP; Colevas AD; Sakr WA; Crawford ED;
J Clin Oncol; 2005 Dec; 23(34):8724-9. PubMed ID: 16314632
[TBL] [Abstract][Full Text] [Related]
7. Cabazitaxel rechallenge at prostate-specific antigen relapse after previous cabazitaxel and docetaxel chemotherapy: case report.
Perry CJ; Sundar S
Clin Genitourin Cancer; 2012 Sep; 10(3):207-9. PubMed ID: 22445962
[No Abstract] [Full Text] [Related]
8. Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer.
Sella A; Sternberg C; Kovel S; Yarom N; Skoneczna I
BJU Int; 2007 Sep; 100(3):533-5. PubMed ID: 17559560
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel-prednisolone combination therapy for Japanese patients with hormone-refractory prostate cancer: a single institution experience.
Miura N; Numata K; Kusuhara Y; Shirato A; Hashine K; Sumiyoshi Y
Jpn J Clin Oncol; 2010 Nov; 40(11):1092-8. PubMed ID: 20587613
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan.
Naito S; Tsukamoto T; Koga H; Harabayashi T; Sumiyoshi Y; Hoshi S; Akaza H
Jpn J Clin Oncol; 2008 May; 38(5):365-72. PubMed ID: 18417502
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer.
Dahut WL; Gulley JL; Arlen PM; Liu Y; Fedenko KM; Steinberg SM; Wright JJ; Parnes H; Chen CC; Jones E; Parker CE; Linehan WM; Figg WD
J Clin Oncol; 2004 Jul; 22(13):2532-9. PubMed ID: 15226321
[TBL] [Abstract][Full Text] [Related]
13. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.
Machiels JP; Mazzeo F; Clausse M; Filleul B; Marcelis L; Honhon B; D'Hondt L; Dopchie C; Verschaeve V; Duck L; Verhoeven D; Jousten P; Bonny MA; Moxhon AM; Tombal B; Kerger J
J Clin Oncol; 2008 Nov; 26(32):5261-8. PubMed ID: 18794543
[TBL] [Abstract][Full Text] [Related]
14. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
15. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
[TBL] [Abstract][Full Text] [Related]
16. Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.
Ladoire S; Eymard JC; Zanetta S; Mignot G; Martin E; Kermarrec I; Mourey E; Michel F; Cormier L; Ghiringhelli F
Anticancer Res; 2010 Oct; 30(10):4317-23. PubMed ID: 21036758
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W
Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer.
Amato RJ; Sarao H
Clin Genitourin Cancer; 2006 Mar; 4(4):281-6. PubMed ID: 16729912
[TBL] [Abstract][Full Text] [Related]
19. ECOG: CHAARTED--ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer.
Sweeney CJ
Clin Adv Hematol Oncol; 2006 Aug; 4(8):588-90. PubMed ID: 17111557
[No Abstract] [Full Text] [Related]
20. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
